HomeNewsBusinessReal EstatePain continues for the commercial real estate sector as the pandemic extends into FY2022: ICRA

Pain continues for the commercial real estate sector as the pandemic extends into FY2022: ICRA

The credit outlook for the retail leasing segment remains negative due to the high level of cash flow disruption in Q1 and the rest of the year

June 16, 2021 / 16:35 IST
Story continues below Advertisement
The housing sector continues to experience an infusion of last-mile funding for project completion.
The housing sector continues to experience an infusion of last-mile funding for project completion.

The commercial real estate sector will continue to face significant pressure in the near term owing to the continuing impact of the COVID-19 pandemic on both the office and retail leasing segments. The evolving work practices in response to the pandemic may create a temporary deferment of leasing decisions or a permanent reduction in the demand for real estate space, a report by ICRA on Impact of the Second Wave on Indian Commercial Real Estate Sector has said.

The delay in conclusion of new leasing of commercial real estate is on account of multiple factors including restrictions on international travel and deferment of decision making until there is clarity on employees returning to offices at earlier numbers. To some extent, corporates could also be evaluating the potential for them to reduce their real estate footprint through implementation of hybrid work models including work-from-home, flexi-seating, it said.

Story continues below Advertisement

It said that vacancies increased post first wave across geographies and inched further upwards with onset of second wave. Occupancy too declined for listed developers, although extent varied across geographies.

Assets primarily occupied by large IT/ITES or captive delivery centres of MNCs have seen relatively lower impact than city centric properties, it said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show